201 related articles for article (PubMed ID: 30578334)
1. Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases.
Swigris JJ; Brown KK; Abdulqawi R; Buch K; Dilling DF; Koschel D; Thavarajah K; Tomic R; Inoue Y
Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578334
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary fibrosis: from pathogenesis to clinical decision-making.
Koudstaal T; Funke-Chambour M; Kreuter M; Molyneaux PL; Wijsenbeek MS
Trends Mol Med; 2023 Dec; 29(12):1076-1087. PubMed ID: 37716906
[TBL] [Abstract][Full Text] [Related]
3. World Trade Center Health Program best practices for the diagnosis and treatment of fibrosing interstitial lung diseases.
de la Hoz RE; Johannson KA
Arch Environ Occup Health; 2023; 78(4):232-235. PubMed ID: 36632789
[TBL] [Abstract][Full Text] [Related]
4. Monitoring and management of fibrosing interstitial lung diseases: a narrative review for practicing clinicians.
Nambiar AM; Walker CM; Sparks JA
Ther Adv Respir Dis; 2021; 15():17534666211039771. PubMed ID: 34477452
[TBL] [Abstract][Full Text] [Related]
5. Walking the path of treatable traits in interstitial lung diseases.
Amati F; Spagnolo P; Ryerson CJ; Oldham JM; Gramegna A; Stainer A; Mantero M; Sverzellati N; Lacedonia D; Richeldi L; Blasi F; Aliberti S
Respir Res; 2023 Oct; 24(1):251. PubMed ID: 37872563
[TBL] [Abstract][Full Text] [Related]
6. Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement.
Aronson KI; Danoff SK; Russell AM; Ryerson CJ; Suzuki A; Wijsenbeek MS; Bajwah S; Bianchi P; Corte TJ; Lee JS; Lindell KO; Maher TM; Martinez FJ; Meek PM; Raghu G; Rouland G; Rudell R; Safford MM; Sheth JS; Swigris JJ
Am J Respir Crit Care Med; 2021 Jul; 204(2):e3-e23. PubMed ID: 34283696
[No Abstract] [Full Text] [Related]
7. Is it time to include oxygen needs as an endpoint in clinical trials in patients with fibrosing interstitial lung disease? If so, how?
Aronson K; Jacobs SS; Repola D; Swigris JJ
BMJ Open Respir Res; 2023 Jul; 10(1):. PubMed ID: 37419519
[TBL] [Abstract][Full Text] [Related]
8. Watching an Evolution in Progress, Cutting-Edge Research Transforming Outcomes in Interstitial Lung Disease: Introduction to an
Maher TM; Podolanczuk AJ; Drake WP; Sime PJ; Eickelberg O; DeMeo DL; Richeldi L
Am J Respir Crit Care Med; 2024 May; 209(9):1049-1050. PubMed ID: 38690973
[No Abstract] [Full Text] [Related]
9. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.
Cottin V; Hirani NA; Hotchkin DL; Nambiar AM; Ogura T; Otaola M; Skowasch D; Park JS; Poonyagariyagorn HK; Wuyts W; Wells AU
Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578335
[TBL] [Abstract][Full Text] [Related]
10. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype.
Olson AL; Gifford AH; Inase N; Fernández Pérez ER; Suda T
Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578336
[TBL] [Abstract][Full Text] [Related]
11. Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease.
Harari S
Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578338
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
13. Fibrosing interstitial lung diseases: knowns and unknowns.
Cottin V; Wollin L; Fischer A; Quaresma M; Stowasser S; Harari S
Eur Respir Rev; 2019 Mar; 28(151):. PubMed ID: 30814139
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of content and quality of idiopathic pulmonary fibrosis review articles.
Milne KM; Chan C; Fisher JH; de Boer K; Ryerson CJ
ERJ Open Res; 2018 Oct; 4(4):. PubMed ID: 30588478
[TBL] [Abstract][Full Text] [Related]
15. The natural history of progressive fibrosing interstitial lung diseases.
Brown KK; Martinez FJ; Walsh SLF; Thannickal VJ; Prasse A; Schlenker-Herceg R; Goeldner RG; Clerisme-Beaty E; Tetzlaff K; Cottin V; Wells AU
Eur Respir J; 2020 Jun; 55(6):. PubMed ID: 32217654
[TBL] [Abstract][Full Text] [Related]
16. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
Wijsenbeek M; Kreuter M; Olson A; Fischer A; Bendstrup E; Wells CD; Denton CP; Mounir B; Zouad-Lejour L; Quaresma M; Cottin V
Curr Med Res Opin; 2019 Nov; 35(11):2015-2024. PubMed ID: 31328965
[No Abstract] [Full Text] [Related]
17. Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis.
Dutta P; Funston W; Mossop H; Ryan V; Jones R; Forbes R; Sen S; Pearson J; Griffin SM; Smith JA; Ward C; Forrest IA; Simpson AJ
Thorax; 2019 Apr; 74(4):346-353. PubMed ID: 30610155
[TBL] [Abstract][Full Text] [Related]
18. Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases.
Holtze C; Flaherty K; Kreuter M; Luppi F; Moua T; Vancheri C; Scholand MB
Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578337
[TBL] [Abstract][Full Text] [Related]
19. Progression of fibrosing interstitial lung disease.
Wong AW; Ryerson CJ; Guler SA
Respir Res; 2020 Jan; 21(1):32. PubMed ID: 31996266
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
